1 / 61

Who needs a PCI in 2008…. Multivessel disease

Who needs a PCI in 2008…. Multivessel disease. Dr Adrian Banning Consultant Cardiologist John Radcliffe Oxford. Dr Adrian Banning - potential conflicts of interest – 07-08 Research funding Boston Scientfic Cordis- J/J Advisory Boards Boston Scientific Elli Lilly Abbott Medtronic

gudrun
Download Presentation

Who needs a PCI in 2008…. Multivessel disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Who needs a PCI in 2008….Multivessel disease Dr Adrian Banning Consultant Cardiologist John Radcliffe Oxford

  2. Dr Adrian Banning - potential conflicts of interest – 07-08 Research funding Boston Scientfic Cordis- J/J Advisory Boards Boston Scientific Elli Lilly Abbott Medtronic Conference expenses Sanofi

  3. Who needs a PCI in 2008…Multivessel disease • Can we do it? • Can we do it as well as/better than the surgeons? • What are the issues? • When (in 2008) shouldn’t we do it?

  4. Multivessel stenting is off label……. but…….

  5. Necessity is the mother of in vention t e r

  6. Can we do it ? 68 yrs old Stable angina Not diabetic Normal LV 3 vessel disease SYNTAX score 15

  7. Of course we can do it..... • 33 x 3.0mm SES to LAD • KB to D1

  8. Of course we can do it….but should we? 13 x 2.5mm SES to PDA 13 x 2.75 mm SES to LCX

  9. Is there an evidence base for stenting in focal multivessel disease?

  10. So we can do it – safely?

  11. Can we get the same outcome as the surgeons? (sometimes)

  12. But what about this one? 67 yrs old Stable Angina diabetic Normal LV 3 vessel disease SYNTAX score 41

  13. 306 patients with 3 VD treated with PCI ARTS II trial Serruys PW, ACC 2006

  14. Multi-vessel Disease & SES: All Patients 12 months follow-up - MACE Independently adjudicated events p <0.001 p <0.001 p <0.01 % Jilaihawi H, Gershlick A, et al, BCS May 2005

  15. Stent thrombosis after MV stenting %

  16. Syntax the Oxford experience 42 pts (5th world )

  17. What if Syntax is favourable to stents?What are the issues – at the coal face?

  18. The key issues • Complete revascularisation • Long stents - Procedural MI • Calcification – limiting stent expansion

  19. Issues in MVD (1)Complete revascularisation? The evidence

  20. Courage: the main study

  21. Length is no longer important or is it?

  22. Issues in MVD stenting (2) Long stent - Procedural MI Procedural enzyme elevation in Taxus VI

  23. Background

  24. Correlation of cTnI rise with new myocardial hyperenhancement 18 r= 0.78 p<0.001 n = 45 13 New Hyperenhancement (grams) 8 3 0 2 5 8 Troponin rise at 20 hrs (ųg/L)

  25. “Adjacent” Hyperenhancement New HE-8.5g cTnI 4.8µg/L

  26. Distal pattern caused by embolisation

  27. Circulation 2007;116: 2634-53

  28. Circulation 2007;116: 2634-53

  29. 234 potentially relevant citations identified and screened for retrieval 204 citations excluded by title or abstract examination 30 reports retrieved for detailed evaluation 15 reports excluded because reviews, incomplete reporting, acute coronary syndromes included, raised baseline TnI included 15 studies finally included What does the new definition of AMI mean in practice? Inclusion criteria: 1) normal baseline Troponin, 2) scheduled procedure for stable or unstable angina 3) post procedure Troponin assessed, 4) complete reporting of procedural outcome and follow up data

  30. Troponin level and MACE

  31. Troponin level and death

  32. Troponin elevation during PCI • 100 pts undergoing PCI • 28 some elevation of troponin • 15 diagnosis of MI • 5 MACE in the next 18 months

  33. Troponin elevation during PCI • 100 pts undergoing PCI • 28 some elevation of troponin • 15 diagnosis of MI • 5 MACE in the next 18 months • Look after your side branches! • Theres not much we can do about embolisation

  34. Issues in MVD (3) Calcification - limiting stent expansion • Incomplete expansion remains a major cause of stent thrombosis • Incomplete expansion of DES is a major cause of stenosis and therefore re-stenosis

  35. If all this new technology is so great why don’t UK surgeons use it?

  36. Graft occlusion in 2007…. at least stent thrombosis is <1%!

  37. Patient with 3 vessel disease M-C Morice, PCR 2006 What is the periprocedural risk eg. Euroscore? What is the lesion complexity, e.g. Syntax score? Unacceptable Acceptable PCI with DES What is the patient’s clinical status? Stable Unstable Most complex lesion first? -e.g. CTO PCI of culprit lesion Contrast volume? Renal Status? Evaluation of other lesions Outcome? Failure Success Acceptable Surgery Complete revascularization Staged procedure

  38. Multivessel PCI in 2008 If syntax shows equivalence- of course we can do it but to compete effectively with surgical revascularisation we must ensure complete revascularisation optimal stent expansion minimise myocardial injury

  39. Multivessel PCI in 2008 If Syntax shows equivalence –remember: • complete revascularisation • optimal stent expansion • minimise myocardial injury This is HARD WORK and not easy for the patient or the interventionalist XXXX

  40. 24 h post CABG 24 h post multivessel PCI Slide Acknowledgements K Dawkins P Urban L Testa & team at JR

More Related